From a cancer drug fund to value based pricing of drugs.
Duerden
Martin
M
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000191:economics / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D004739:England; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000191:economics; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000191:economics / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D000077157:Sorafenib; D014852:Wales
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib